Cargando…
Proton Magnetic Resonance Spectroscopy in Common Dementias—Current Status and Perspectives
Dementia occurs mainly in the elderly and is associated with cognitive decline and impairment of activities of daily living. The most common forms of dementia are Alzheimer’s disease (AD), vascular dementia (VD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). To date, there are...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424040/ https://www.ncbi.nlm.nih.gov/pubmed/32848938 http://dx.doi.org/10.3389/fpsyt.2020.00769 |
_version_ | 1783570254005272576 |
---|---|
author | Maul, Stephan Giegling, Ina Rujescu, Dan |
author_facet | Maul, Stephan Giegling, Ina Rujescu, Dan |
author_sort | Maul, Stephan |
collection | PubMed |
description | Dementia occurs mainly in the elderly and is associated with cognitive decline and impairment of activities of daily living. The most common forms of dementia are Alzheimer’s disease (AD), vascular dementia (VD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). To date, there are no causal options for therapy, but drug and non-drug treatments can positively modulate the course of the disease. Valid biomarkers are needed for the earliest possible and reliable diagnosis, but so far, such biomarkers have only been established for AD and require invasive and expensive procedures. In this context, proton magnetic resonance spectroscopy ((1)H-MRS) provides a non-invasive and widely available technique for investigating the biochemical milieu of brain tissue in vivo. Numerous studies have been conducted for AD, but for VD, DLB, and FTD the number of studies is limited. Nevertheless, MRS can detect measurable metabolic alterations in common dementias. However, most of the studies conducted are too heterogeneous to assess the potential use of MRS technology in clinical applications. In the future, technological advances may increase the value of MRS in dementia diagnosis and treatment. This review summarizes the results of MRS studies conducted in common dementias and discusses the reasons for the lack of transfer into clinical routine. |
format | Online Article Text |
id | pubmed-7424040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74240402020-08-25 Proton Magnetic Resonance Spectroscopy in Common Dementias—Current Status and Perspectives Maul, Stephan Giegling, Ina Rujescu, Dan Front Psychiatry Psychiatry Dementia occurs mainly in the elderly and is associated with cognitive decline and impairment of activities of daily living. The most common forms of dementia are Alzheimer’s disease (AD), vascular dementia (VD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). To date, there are no causal options for therapy, but drug and non-drug treatments can positively modulate the course of the disease. Valid biomarkers are needed for the earliest possible and reliable diagnosis, but so far, such biomarkers have only been established for AD and require invasive and expensive procedures. In this context, proton magnetic resonance spectroscopy ((1)H-MRS) provides a non-invasive and widely available technique for investigating the biochemical milieu of brain tissue in vivo. Numerous studies have been conducted for AD, but for VD, DLB, and FTD the number of studies is limited. Nevertheless, MRS can detect measurable metabolic alterations in common dementias. However, most of the studies conducted are too heterogeneous to assess the potential use of MRS technology in clinical applications. In the future, technological advances may increase the value of MRS in dementia diagnosis and treatment. This review summarizes the results of MRS studies conducted in common dementias and discusses the reasons for the lack of transfer into clinical routine. Frontiers Media S.A. 2020-08-06 /pmc/articles/PMC7424040/ /pubmed/32848938 http://dx.doi.org/10.3389/fpsyt.2020.00769 Text en Copyright © 2020 Maul, Giegling and Rujescu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Maul, Stephan Giegling, Ina Rujescu, Dan Proton Magnetic Resonance Spectroscopy in Common Dementias—Current Status and Perspectives |
title | Proton Magnetic Resonance Spectroscopy in Common Dementias—Current Status and Perspectives |
title_full | Proton Magnetic Resonance Spectroscopy in Common Dementias—Current Status and Perspectives |
title_fullStr | Proton Magnetic Resonance Spectroscopy in Common Dementias—Current Status and Perspectives |
title_full_unstemmed | Proton Magnetic Resonance Spectroscopy in Common Dementias—Current Status and Perspectives |
title_short | Proton Magnetic Resonance Spectroscopy in Common Dementias—Current Status and Perspectives |
title_sort | proton magnetic resonance spectroscopy in common dementias—current status and perspectives |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424040/ https://www.ncbi.nlm.nih.gov/pubmed/32848938 http://dx.doi.org/10.3389/fpsyt.2020.00769 |
work_keys_str_mv | AT maulstephan protonmagneticresonancespectroscopyincommondementiascurrentstatusandperspectives AT gieglingina protonmagneticresonancespectroscopyincommondementiascurrentstatusandperspectives AT rujescudan protonmagneticresonancespectroscopyincommondementiascurrentstatusandperspectives |